BriaCell announces the initiation of GMP manufacturing of Bria-Pros+

BriaCell Therapeutics announces the initiation of Good Manufacturing Practice, GMP, manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. GMP manufacturing of Bria-Pros+ will provide clinical supplies for planned clinical trial use. “Building upon the compelling pre-clinical proof-of-concept data presented at the Society for the Immunotherapy of Cancer meeting in 2023, BriaCell’s proprietary platform technology holds significant potential to benefit patients across a spectrum of cancers. We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William Williams, BriaCell’s President and CEO. “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application. We eagerly anticipate completing Investigational New Drug (IND)-enabling studies during 2024 with Bria-Pros+.”